Hydrogen-Induced Mucus Barrier Disruption Augments Inhaled RNA Therapeutics to Reverse Pulmonary Fibrosis

Pulmonary fibrosis (PF) is a fatal lung interstitial disease with limited treatments. Recent advancements in pulmonary gene therapies have shown potential to halt or even reverse PF, particularly by focusing on correcting gene mutations in alveolar epithelial cells (1). Despite these advancements, a clinical trial using nebulized gene-liposome complex for inhaled CFTR mRNA failed to show significant efficacy in cystic fibrosis patients, underscoring the need for more effective pulmonary delivery systems (2). Driven by the need for efficient RNA delivery to the lungs and the potential for long-lasting treatment of PF, we herein present a highly efficient aerosol inhalation system.